Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: docetaxel
Drug: carboplatin

First Posted Date: 2007-08-24

Last Posted Date: 2011-08-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 260

Registration Number: NCT00520676

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Carboplatin
Drug: Abraxane

First Posted Date: 2007-08-23

Last Posted Date: 2012-03-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 47

Registration Number: NCT00520000

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Papillary Serous Mullerian Tumor
Clear Cell Mullerian Tumor

Interventions: Drug: bevacizumab
Drug: paclitaxel
Drug: erlotinib
Drug: carboplatin

First Posted Date: 2007-08-23

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00520013

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: carboplatin
Drug: bevacizumab

First Posted Date: 2007-08-16

Last Posted Date: 2014-04-15

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00517361

Locations: 🇺🇸
Oncology Specialists, Park Ridge, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1

Completed

Conditions: Carboplatin
Triple Negative Metastatic Breast Cancer
Advanced Ovarian Cancer
Paclitaxel

Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Drug: Carboplatin
Drug: Paclitaxel
Drug: Paclitaxel + Carboplatin

First Posted Date: 2007-08-15

Last Posted Date: 2024-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 189

Registration Number: NCT00516724

Locations: 🇬🇧
Research Site, London, United Kingdom

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2007-08-10

Last Posted Date: 2020-09-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 121

Registration Number: NCT00514540

Locations: 🇺🇸
University of California-San Francisco, San Francisco, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2007-08-09

Last Posted Date: 2014-01-10

Lead Sponsor: Raghu Nandan, M.D., Inc

Target Recruit Count: 39

Registration Number: NCT00514293

Locations: 🇺🇸
R. Nandan M.D. Incorporated, Lakewood, California, United States

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: bevacizumab

First Posted Date: 2007-08-09

Last Posted Date: 2017-08-01

Lead Sponsor: David O'Malley

Target Recruit Count: 38

Registration Number: NCT00513786

Locations: 🇺🇸
Ohio State University-Division of Gyn Oncology, Columbus, Ohio, United States

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Panitumumab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Intensity Modulated Radiation Therapy
Drug: 5-Fluorouracil
Drug: Docetaxel
Drug: Cisplatin

First Posted Date: 2007-08-08

Last Posted Date: 2017-03-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 34

Registration Number: NCT00513383

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: AMG 951 (rhApo2L/TRAIL)
Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2007-07-30

Last Posted Date: 2016-06-14

Lead Sponsor: Amgen

Target Recruit Count: 213

Registration Number: NCT00508625

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy